Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Hironaga SatakeKeun-Wook LeeHyun Cheol ChungJeeyun LeeKensei YamaguchiJen-Shi ChenTakaki YoshikawaKenji AmagaiKun-Huei YehMasahiro GotoYee ChaoKa-On LamShi Rong HanShinichi ShiratoriSukrut ShahKohei ShitaraPublished in: Japanese journal of clinical oncology (2022)
This post hoc analysis showed pembrolizumab monotherapy was associated with numerically improved overall survival and a favourable tolerability profile versus chemotherapy in Asians with programmed death ligand 1-positive advanced gastric cancer/gastrooesophageal junction cancer.This study is registered with ClinicalTrials.gov, NCT02494583.
Keyphrases
- locally advanced
- advanced non small cell lung cancer
- neoadjuvant chemotherapy
- healthcare
- rectal cancer
- squamous cell carcinoma
- open label
- palliative care
- radiation therapy
- papillary thyroid
- randomized controlled trial
- chemotherapy induced
- quality improvement
- combination therapy
- young adults
- squamous cell
- chronic pain
- epidermal growth factor receptor
- health insurance
- study protocol
- tyrosine kinase